Article Text

Download PDFPDF

5PSQ-120 Analysis of the pharmaceutical interventions performed on onco-haematological patients through an onco-haematology pharmacy consultation
  1. C Alarcon-Payer,
  2. A Martín Roldan,
  3. MDM Sánchez Suárez,
  4. C Montero Vílchez,
  5. A Jiménez Morales
  1. Hospital Universitario Virgen de Las Nieves, Servicio de Farmacia, Granada, Spain


Background and Importance In the area of onco-haematology, medication errors are of great importance because oral antineoplastic drugs have a narrow therapeutic margin, complex dosing regimens, possible interactions with other drugs and foods, and low supervision of their self-administration by healthcare professionals, increasing the risk of medication errors.

Aim and Objectives To analyse the pharmaceutical interventions performed on onco-haematology patients seen in an Onco-haematology Pharmacy consultation.

Material and Methods Prospective observational study of onco-haematology patients in a tertiary hospital for a period of one year. To identify the type of intervention performed, a database was created using an Excel ® spreadsheet to record and categorise it. Once identified, it was entered as an episode in the patient‘s clinical history in the Diraya Clinica® programme so that the clinician could consult it in the patient‘s evolution. Finally, errors, interactions and adverse reactions avoided by performing these interventions were recorded.

Results A total of 35 onco-haematology patients underwent pharmaceutical interventions. 55% men and 45% women. The median age was 64 years. The patients belonged to two clinical services, 40.8% to Haematology and 59.2% to Oncology. The onco-haematological pathologies where most interventions were performed were: Prostate Cancer (30%), Colon Cancer (25%), Chronic Lymphatic Leukaemia (16%), Multiple Myeloma (10%), Ovarian Cancer (7%), Brain Tumours (5%), Lung Cancer (4%), Breast Cancer (3%). 45% of the pharmaceutical interventions performed were incorrect doses of antineoplastic drugs, 25% relevant drug interactions, 18% omission of the drug, 10% incorrect frequency of administration and 2% detected adverse reactions. The most frequent dose errors were poor adjustment for renal function (40%), failure to write the dose in the patient‘s clinical course (30%), failure to adjust for liver failure (20%), poor adjustment for body surface area (10%). 100% of the errors were detected in the pharmaceutical validation process during the dispensing of oral cytostatics. 100% of the pharmaceutical interventions were entered in the patient‘s clinical history as a clinical report. 97% were accepted and prevented 97% of medication errors in patients.

Conclusion and Relevance Pharmaceutical interventions have proven to be an effective tool to contribute to the achievement of the patient‘s therapeutic goals.

References and/or Acknowledgements 1. J Oncol Pract 2011;7(1): 7–12.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.